Search results for "ORPHAN DRUG|Designated|Treatment of BRAF-mutant Non-Small Cell Lung Cancer" in comments (approximate match)
Showing 1 - 1 of 1 results
Class (Stereo):
CHEMICAL (ABSOLUTE)
Encorafenib, also known as BRAFTOVI or LGX818, is an orally available mutated BRaf V600E inhibitor with potential antineoplastic activity, which was developed by Novartis. LGX818 possesses selective anti-proliferative and apoptotic activity in cells ...